Since 1996, Cardinal Partners has been investing in disruptive healthcare technology-enabled services and life sciences companies providing top quartile returns. We position ourselves as an early/growth stage partner to entrepreneurs, usually participating as the first institutional investor in the company, and selectively playing co-founding roles at a company’s inception. The deep experience and superior investment returns of Cardinal have demonstrated that we know how to successfully build durable, valuable companies throughout multiple business and economic cycles.
We believe that due to the ongoing waves of change affecting the healthcare systems, insurance and regulatory reform, this is an excellent time to invest in early/growth stage companies that offer innovations in delivering more care to more people, for less money. Over the course of their careers, the Cardinal Partners team has invested in over one hundred growth companies and participated in over 25 IPOS. Since 1997 alone, companies funded by Cardinal have a cumulative market valuation exceeding $15 Billion. Cardinal’s investors include university endowments, foundations, pension funds, banks, and insurance companies.
Our breadth of experience in early/growth stage health care investing – combined with strong networks in the academic, clinical, industry and investment communities; committed and sustained engagement with each portfolio company – positions Cardinal to be a leading next generation venture capital firm, producing superior returns for our investment partners.
Our Portfolio in the news
We believe that we are at the beginning of a transformational wave where technology has, and will, radically affect the diagnosis and delivery of health care.
QPID Artificial Intelligence (AI) software uses NLP and machine learning to generate fact from medical records for CDS, CCM and Quality Reporting. Cardinal Partners was a participant in “spin-out” financing from Partners HealthCare. QPID Health was acquired by eviCore healthcare, a leading medical benefits management company.
Cubist Pharmaceuticals was a U.S. biopharmaceutical company with activities spanning from research and development to commercialization of pharmaceutical products. Its main products target pathogens like MRSA. In 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion) as entree to the market for drugs that can combat superbugs.